ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories
CompanyDeals

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Synmosa Biopharma (TPE: 4114) announced that it has signed an exclusive licensing, supply, and commercialization agreement with Nxera Pharma Japan, a subsidiary of Japan's Nxera Pharma, for the insomnia therapy…

Huadong Medicine's Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Pfizer's Hympavzi Wins NMPA Approval for a New Indication in China – World's First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Astellas Pharma Licenses Evopoint's CLDN18.2 ADC for Global Development
CompanyDeals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

GSK's Blenrep Recommended for EU Approval in Multiple Myeloma
CompanyDrug

GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma

Kelun-Biotech's Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer
CompanyDrug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
CompanyDrug

Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC

GSK's Blenrep Receives Marketing Approval in Japan for Multiple Myeloma
CompanyDrug

GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma

Zai Lab's ZL-1310 Receives FDA Fast Track Designation for SCLC
CompanyDrug

Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC

CSPC Pharmaceutical's CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
CompanyDrug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
CompanyDrug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Show More